Nathaniel Gould – University of Haifa

Alzheimer disease (AD) develops slowly and has no effective treatment, yet we have recently demonstrated that a major, novel target in AD is the little-known enzyme quinone reductase 2 (QR2). Inhibiting QR2 is expected to both enhance cognition and attenuate AD progression. We aim to develop a first-in-class AD drug based on uniquely soluble, bioavailable, non-toxic and highly specific QR2 inhibitors developed in our lab, and thus preclinical development of our QR2 inhibitors may provide a novel drug to treat AD via a previously unexplored mechanism.

Other Presentations

Aevum – Gail Chan, PhD – View


AKScientist – Aarti Kuver, PhD – View


AmyloiDia – Vladana Vukojevic, PhD View


ASDERA LLC – Knut Wittkowski, PhD – View


BIORCHESTRA Co., Ltd – Branden Ryu, PhD – View


BioTrillion, Inc. – Savan Devani, MS – View


BrainCures – Krzysztof Potempa, PhD – View


BrainTrip – Jurij Dreo, MD – View


Diadem – Simona Piccirella, PhD – View


Generian Pharmaceuticals, Inc. – Toren Finkel, MD, PhD – View


Lauren Sciences LLC – Susan Rosenbaum, JD –View


LumeNeuro – Ron Dennis – View


Marvel Biotechnology – Mark Williams, PhD, MBA – View


Memandis – Nareem Surya View


MGH/Harvard Medical School – Xudong Huang, PhD – View


Neuropath Therapeutics Limited – Julie Kelly, PhD – View


Oxford Brain Diagnostics Ltd – Steven Chance, PhD – View


Winterlight Labs – Nicola Johnson, MS – View